Ibrutinib in CLL, — Mantle Cell Lymphoma and Waldenstrom's

Ibrutinib is a targeted therapy, not a chemotherapy drug. It blocks a specific protein called BTK that leukaemia and lymphoma cells need to survive. Chemotherapy drugs work differently — they damage all rapidly dividing cells, causing hair loss, severe nausea and a drop in blood counts. Ibrutinib has its own side effects, including easy bruising and changes in heart rhythm, but the mechanism and side effect pattern are different from chemotherapy. This distinction matters because the two types of treatment require different precautions.

Response is tracked through regular blood tests, and the markers your team looks for depend on your cancer. In CLL, a falling lymphocyte count in the blood is an early sign the drug is having an effect. In Waldenstrom's macroglobulinaemia, the IgM protein level is usually followed. Results take time to show clearly — do not assume the drug is not working because you feel the same after the first few weeks. Ask your team what they are measuring and when they expect to see the first meaningful change.

Ibrutinib is taken continuously, not in short courses. NCCN guidance describes it as ongoing treatment continued for as long as it is working and tolerated. There is no fixed end date — your oncologist reviews whether the treatment is still benefiting you at each follow-up appointment. This is a significant difference from how many patients think of cancer treatment, where a course ends and stops. Some people take ibrutinib for many years; others need a change earlier because of side effects or disease progression.

Grapefruit and grapefruit juice should be avoided — they affect an enzyme that processes ibrutinib and can cause more of the drug to build up in your body than intended. Many antifungal medicines, some antibiotics and certain heart medicines interact through the same liver pathway. Blood thinners are particularly important to discuss with your team, as ibrutinib already raises the risk of bruising and bleeding. Always tell every doctor or dentist you see that you are on ibrutinib before any new medicine is prescribed.

It depends on your cancer type and what you have had before. In CLL, ibrutinib can be given on its own or alongside other agents, depending on your specific situation and your oncologist's recommendation. In mantle cell lymphoma, it is commonly used as a single agent after prior treatment. In Waldenstrom's macroglobulinaemia, it may be given alone or with other medicines. Your oncologist will explain exactly what is planned for you and whether any combination is part of the approach.

Yes. CION oncologists across 35-plus centres manage patients with CLL, mantle cell lymphoma and Waldenstrom's macroglobulinaemia, including those on ibrutinib. Because ibrutinib is an oral medicine taken at home rather than an intravenous treatment given in hospital, most appointments are review and monitoring visits — blood tests, blood pressure checks and clinical assessment. If imaging such as a PET-CT scan is needed as part of your response assessment, CION coordinates this with partner imaging centres.